Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Michael Szarek

Concepts (305)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Acute Coronary Syndrome
36
2025
279
6.170
 Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
40
2025
445
5.170
 Why?
Anticholesteremic Agents
26
2025
153
4.810
 Why?
Antibodies, Monoclonal, Humanized
39
2025
804
4.300
 Why?
Cholesterol, LDL
43
2025
365
3.450
 Why?
Lipoprotein(a)
16
2025
67
3.040
 Why?
Peripheral Arterial Disease
14
2024
475
2.000
 Why?
Glycosides
8
2025
36
1.960
 Why?
Cardiovascular Diseases
25
2025
2111
1.850
 Why?
Heptanoic Acids
20
2014
66
1.690
 Why?
Stroke
14
2022
1120
1.620
 Why?
Myocardial Infarction
17
2024
1046
1.570
 Why?
Pyrroles
20
2014
213
1.560
 Why?
Dyslipidemias
8
2025
176
1.440
 Why?
Ischemic Attack, Transient
4
2020
65
1.390
 Why?
Diabetes Mellitus, Type 2
15
2025
2531
1.220
 Why?
Proprotein Convertase 9
15
2025
73
1.170
 Why?
Treatment Outcome
54
2025
10811
1.130
 Why?
Eicosapentaenoic Acid
2
2025
39
1.090
 Why?
Double-Blind Method
32
2025
1993
1.030
 Why?
Angina, Unstable
7
2019
76
0.990
 Why?
Platelet Aggregation Inhibitors
10
2024
463
0.990
 Why?
Rivaroxaban
12
2024
255
0.930
 Why?
Brain Ischemia
7
2022
338
0.910
 Why?
Hypertriglyceridemia
1
2024
39
0.860
 Why?
Heart Failure
7
2024
2236
0.750
 Why?
Antibodies, Monoclonal
5
2023
1430
0.740
 Why?
Hyperlipoproteinemia Type II
3
2025
35
0.700
 Why?
Renal Insufficiency, Chronic
6
2025
617
0.690
 Why?
Humans
113
2025
137585
0.650
 Why?
Aged
61
2025
23961
0.650
 Why?
Hypercholesterolemia
7
2020
106
0.630
 Why?
Middle Aged
58
2025
33479
0.620
 Why?
Serine Proteinase Inhibitors
4
2025
47
0.610
 Why?
Drug Therapy, Combination
13
2024
1066
0.610
 Why?
Lower Extremity
8
2022
427
0.590
 Why?
Carcinoma, Renal Cell
1
2021
217
0.590
 Why?
Patient Admission
1
2019
197
0.560
 Why?
Simvastatin
4
2010
61
0.540
 Why?
Atherosclerosis
4
2025
415
0.530
 Why?
Kidney Neoplasms
1
2021
403
0.510
 Why?
Male
70
2025
67762
0.490
 Why?
Cholesterol Ester Transfer Proteins
2
2025
20
0.480
 Why?
Aspirin
10
2024
387
0.480
 Why?
Female
69
2025
73304
0.470
 Why?
Risk Factors
19
2024
10388
0.440
 Why?
Patient Readmission
1
2019
697
0.430
 Why?
Venous Thromboembolism
3
2023
316
0.420
 Why?
Global Health
3
2021
386
0.410
 Why?
Ischemia
5
2022
409
0.400
 Why?
Life Change Events
1
2014
151
0.400
 Why?
Secondary Prevention
5
2019
233
0.390
 Why?
Triglycerides
3
2024
524
0.390
 Why?
Career Choice
1
2014
219
0.370
 Why?
Factor Xa Inhibitors
6
2024
172
0.370
 Why?
Markov Chains
2
2010
126
0.360
 Why?
Cholesterol, HDL
6
2025
203
0.360
 Why?
Coronary Artery Bypass
2
2025
234
0.350
 Why?
Cholesterol
3
2022
410
0.330
 Why?
Risk Assessment
8
2024
3457
0.320
 Why?
Time Factors
10
2024
6828
0.310
 Why?
Students, Medical
1
2014
348
0.310
 Why?
Biomarkers
10
2025
4149
0.310
 Why?
Apolipoproteins B
6
2022
43
0.300
 Why?
Coronary Disease
5
2009
385
0.300
 Why?
Infectious Disease Transmission, Vertical
1
2010
184
0.300
 Why?
Vascular Surgical Procedures
2
2021
303
0.290
 Why?
Randomized Controlled Trials as Topic
6
2025
1477
0.290
 Why?
Endovascular Procedures
2
2022
312
0.280
 Why?
Follow-Up Studies
8
2023
5131
0.280
 Why?
Albuminuria
3
2024
185
0.260
 Why?
Models, Statistical
1
2010
669
0.250
 Why?
Proportional Hazards Models
9
2019
1266
0.250
 Why?
Hyperlipoproteinemia Type III
1
2025
3
0.240
 Why?
Saphenous Vein
1
2025
35
0.240
 Why?
Vascular Patency
1
2025
106
0.240
 Why?
Graft Occlusion, Vascular
1
2025
40
0.240
 Why?
Survival Analysis
1
2008
1325
0.230
 Why?
Rosuvastatin Calcium
2
2022
22
0.220
 Why?
HIV-1
1
2010
864
0.220
 Why?
Anticoagulants
4
2023
664
0.220
 Why?
Hemorrhage
6
2024
722
0.210
 Why?
Internship and Residency
1
2014
1147
0.210
 Why?
Glomerular Filtration Rate
2
2024
746
0.200
 Why?
Primary Health Care
1
2014
1738
0.200
 Why?
Fibrin Fibrinogen Degradation Products
1
2023
82
0.200
 Why?
Apolipoproteins E
2
2025
83
0.200
 Why?
Hyperlipidemias
1
2003
120
0.200
 Why?
Antifibrinolytic Agents
1
2023
51
0.200
 Why?
RNA, Small Interfering
1
2024
622
0.190
 Why?
Hospitalization
6
2023
2199
0.180
 Why?
Blood Coagulation Disorders
1
2023
173
0.180
 Why?
Muscles
1
2022
326
0.180
 Why?
Cataract
1
2023
213
0.170
 Why?
Phenylurea Compounds
1
2021
97
0.170
 Why?
Quinolines
1
2021
178
0.160
 Why?
Kidney Diseases
1
2023
408
0.160
 Why?
Renal Insufficiency
1
2021
162
0.160
 Why?
Health Status
1
2024
792
0.150
 Why?
Colonic Neoplasms
1
2021
258
0.150
 Why?
Patient Care Team
1
2024
631
0.150
 Why?
Multifactorial Inheritance
1
2019
174
0.140
 Why?
Thrombosis
1
2022
371
0.140
 Why?
Liver X Receptors
1
2018
31
0.140
 Why?
Venous Thrombosis
1
2020
190
0.140
 Why?
Lipids
4
2010
672
0.140
 Why?
Diabetes Complications
1
2019
227
0.140
 Why?
Atrial Fibrillation
1
2022
388
0.140
 Why?
Cost-Benefit Analysis
1
2020
591
0.130
 Why?
Dose-Response Relationship, Drug
6
2021
2057
0.130
 Why?
Neoplasms, Experimental
1
2018
176
0.130
 Why?
Myeloid-Derived Suppressor Cells
1
2018
66
0.130
 Why?
Prospective Studies
8
2022
7604
0.130
 Why?
Diabetes Mellitus, Type 1
2
2023
3715
0.130
 Why?
Myocardial Ischemia
3
2007
263
0.120
 Why?
HIV Infections
1
2010
2836
0.120
 Why?
Phospholipids
2
2009
223
0.120
 Why?
Hospital Mortality
1
2019
911
0.120
 Why?
Proprotein Convertases
1
2014
16
0.110
 Why?
Killer Cells, Natural
1
2018
449
0.110
 Why?
Adult
15
2025
37929
0.110
 Why?
Receptors, Interleukin-3
1
2014
5
0.110
 Why?
Hypoglycemic Agents
4
2024
1291
0.110
 Why?
Neoplasm Recurrence, Local
1
2021
1079
0.110
 Why?
C-Reactive Protein
3
2022
410
0.110
 Why?
Immunotherapy, Adoptive
1
2018
327
0.110
 Why?
Disease-Free Survival
2
2018
686
0.110
 Why?
Colorectal Neoplasms
1
2021
806
0.110
 Why?
Antigens, Neoplasm
2
2006
319
0.100
 Why?
Coronary Artery Disease
1
2019
698
0.100
 Why?
Skin Neoplasms
2
2014
855
0.100
 Why?
Clinical Trials as Topic
3
2008
1050
0.100
 Why?
Neoplasms
2
2023
2671
0.100
 Why?
Clinical Decision-Making
1
2015
322
0.090
 Why?
Injections, Subcutaneous
2
2024
157
0.090
 Why?
Hematologic Neoplasms
1
2014
156
0.090
 Why?
Developing Countries
1
2014
307
0.090
 Why?
Immunity, Innate
1
2018
828
0.090
 Why?
Recombinant Fusion Proteins
1
2014
665
0.090
 Why?
Diabetes Mellitus
1
2020
1040
0.090
 Why?
Leukemia, Myeloid, Acute
1
2018
630
0.090
 Why?
Sodium-Glucose Transporter 1
2
2020
11
0.090
 Why?
Urban Population
1
2014
479
0.090
 Why?
Heparin
2
2023
261
0.090
 Why?
Dendritic Cells
1
2014
483
0.090
 Why?
Stroke Volume
2
2024
612
0.090
 Why?
Bottle Feeding
1
2010
21
0.090
 Why?
Norway
1
2010
43
0.090
 Why?
Denmark
1
2010
46
0.080
 Why?
Netherlands
1
2010
88
0.080
 Why?
Finland
1
2010
85
0.080
 Why?
Serum Amyloid A Protein
2
2007
33
0.080
 Why?
Sweden
1
2010
101
0.080
 Why?
Likelihood Functions
1
2010
144
0.080
 Why?
Arteries
2
2022
269
0.080
 Why?
Antineoplastic Agents
1
2021
2129
0.080
 Why?
Risk
6
2008
912
0.080
 Why?
Probability
1
2010
304
0.080
 Why?
Myocardial Revascularization
1
2009
73
0.080
 Why?
Statistics, Nonparametric
1
2010
431
0.080
 Why?
Aged, 80 and over
7
2020
7635
0.080
 Why?
Hydroxymethylglutaryl CoA Reductases
1
2009
14
0.080
 Why?
Melanoma
2
2006
760
0.070
 Why?
Biomarkers, Tumor
2
2006
1276
0.070
 Why?
United States Government Agencies
1
2008
5
0.070
 Why?
Practice Guidelines as Topic
3
2019
1587
0.070
 Why?
Biometry
1
2008
70
0.070
 Why?
Inflammation
4
2023
2837
0.070
 Why?
Tissue Plasminogen Activator
2
2022
224
0.070
 Why?
Postoperative Complications
1
2019
2654
0.070
 Why?
Cell Line, Tumor
3
2021
3412
0.070
 Why?
Counseling
1
2010
391
0.070
 Why?
Incidence
3
2022
2804
0.070
 Why?
Recurrence
4
2019
1060
0.070
 Why?
United States
3
2019
14841
0.070
 Why?
Decision Making
1
2014
900
0.060
 Why?
Breast Feeding
1
2010
440
0.060
 Why?
Fibrinolytic Agents
2
2022
270
0.060
 Why?
Reactive Oxygen Species
1
2009
622
0.060
 Why?
Data Interpretation, Statistical
1
2008
363
0.060
 Why?
Dicarboxylic Acids
1
2025
9
0.060
 Why?
Acute Disease
3
2021
1007
0.060
 Why?
Clinical Trials, Phase III as Topic
1
2025
106
0.060
 Why?
Medication Adherence
1
2009
467
0.060
 Why?
Esters
1
2025
76
0.060
 Why?
Lipoproteins, HDL
1
2005
77
0.060
 Why?
Cancer Vaccines
1
2006
172
0.060
 Why?
Heterozygote
1
2025
293
0.060
 Why?
Antigen-Antibody Complex
1
2004
90
0.060
 Why?
CD40 Ligand
1
2004
41
0.060
 Why?
Lipoproteins, LDL
1
2004
116
0.050
 Why?
Subtilisins
1
2023
10
0.050
 Why?
Thromboplastin
1
2023
74
0.050
 Why?
Ezetimibe
1
2022
24
0.050
 Why?
Fatty Acids
1
2025
443
0.050
 Why?
Creatine Kinase
1
2022
79
0.050
 Why?
Numbers Needed To Treat
1
2021
7
0.050
 Why?
Plasma Membrane Neurotransmitter Transport Proteins
1
2021
6
0.050
 Why?
Metabolic Syndrome
1
2005
354
0.050
 Why?
Pharmacogenomic Testing
1
2022
64
0.050
 Why?
Creatine
1
2021
57
0.050
 Why?
Inflammation Mediators
1
2004
513
0.040
 Why?
Goals
1
2022
170
0.040
 Why?
Receptors, Immunologic
1
2022
216
0.040
 Why?
Algorithms
1
2008
1704
0.040
 Why?
Membrane Transport Proteins
1
2021
162
0.040
 Why?
Diabetic Nephropathies
1
2024
294
0.040
 Why?
Proto-Oncogene Proteins p21(ras)
1
2021
267
0.040
 Why?
Disease Progression
2
2024
2757
0.040
 Why?
Mycoses
1
2020
79
0.040
 Why?
Placebo Effect
1
2019
25
0.040
 Why?
Ventricular Function, Left
1
2023
534
0.040
 Why?
Odds Ratio
3
2009
1070
0.040
 Why?
Mice, Nude
1
2021
698
0.040
 Why?
Diarrhea
1
2020
184
0.040
 Why?
Hypotension
1
2020
122
0.040
 Why?
Patient Education as Topic
1
2024
766
0.040
 Why?
Age Factors
1
2007
3295
0.040
 Why?
Antigens, CD
1
2022
521
0.040
 Why?
Propensity Score
1
2021
294
0.040
 Why?
Sex Characteristics
1
2024
762
0.040
 Why?
Transplantation, Haploidentical
1
2018
22
0.040
 Why?
Diabetic Ketoacidosis
1
2020
201
0.040
 Why?
Sex Factors
1
2024
2071
0.040
 Why?
American Heart Association
1
2019
306
0.040
 Why?
Nerve Tissue Proteins
1
2021
596
0.030
 Why?
Cell Count
1
2018
324
0.030
 Why?
Mice, SCID
1
2018
367
0.030
 Why?
Erythrocytes
1
2022
700
0.030
 Why?
Cohort Studies
2
2022
5742
0.030
 Why?
Muscular Diseases
2
2008
114
0.030
 Why?
Infant
1
2010
9465
0.030
 Why?
Vascular Diseases
1
2019
243
0.030
 Why?
Morbidity
1
2017
324
0.030
 Why?
Mice, Inbred NOD
1
2018
601
0.030
 Why?
Liver
1
2024
1943
0.030
 Why?
Kidney
1
2024
1468
0.030
 Why?
Apolipoproteins
2
2007
33
0.030
 Why?
Immunoglobulin M
2
2009
289
0.030
 Why?
Membrane Proteins
1
2022
1164
0.030
 Why?
Genome-Wide Association Study
1
2022
1431
0.030
 Why?
Cytoplasm
2
2006
274
0.030
 Why?
Cause of Death
1
2017
434
0.030
 Why?
Tissue Donors
1
2018
425
0.030
 Why?
Xenograft Model Antitumor Assays
1
2018
872
0.030
 Why?
Fluorobenzenes
1
2014
16
0.030
 Why?
Interleukin-3
1
2014
25
0.030
 Why?
Syndrome
2
2007
358
0.030
 Why?
Thrombolytic Therapy
1
2015
142
0.030
 Why?
Diphtheria Toxin
1
2014
66
0.030
 Why?
Cell Proliferation
1
2021
2475
0.030
 Why?
Serine Endopeptidases
1
2014
123
0.030
 Why?
Oxidation-Reduction
2
2009
1060
0.030
 Why?
Multivariate Analysis
2
2007
1509
0.030
 Why?
Acute Kidney Injury
1
2020
815
0.020
 Why?
Immunoglobulin G
2
2009
893
0.020
 Why?
Prognosis
3
2005
4030
0.020
 Why?
Quality of Life
1
2024
2892
0.020
 Why?
Mice
2
2021
17787
0.020
 Why?
Child, Preschool
2
2005
11074
0.020
 Why?
Neoplasm Staging
2
2006
1389
0.020
 Why?
CD8-Positive T-Lymphocytes
1
2018
900
0.020
 Why?
Interleukin-6
2
2007
778
0.020
 Why?
Molecular Targeted Therapy
1
2014
411
0.020
 Why?
Pyrimidines
1
2014
470
0.020
 Why?
Adolescent
3
2006
21513
0.020
 Why?
Mice, Knockout
1
2018
3015
0.020
 Why?
Sulfonamides
1
2014
513
0.020
 Why?
Predictive Value of Tests
2
2006
2031
0.020
 Why?
Mutation
1
2021
3958
0.020
 Why?
Pilot Projects
1
2015
1710
0.020
 Why?
Autoantibodies
2
2009
1496
0.020
 Why?
Ireland
1
2008
30
0.020
 Why?
Apolipoprotein A-I
1
2008
30
0.020
 Why?
Thromboembolism
1
2009
119
0.020
 Why?
Europe
1
2009
414
0.020
 Why?
Lipoproteins
1
2009
168
0.020
 Why?
United Kingdom
1
2008
318
0.020
 Why?
Animals
2
2021
36940
0.020
 Why?
Drug Prescriptions
1
2009
245
0.020
 Why?
Child
2
2005
21935
0.020
 Why?
Severity of Illness Index
1
2015
2828
0.020
 Why?
Cerebral Infarction
1
2006
44
0.020
 Why?
Gastrointestinal Diseases
1
2008
209
0.020
 Why?
Hematuria
1
2005
12
0.020
 Why?
ROC Curve
1
2007
554
0.020
 Why?
Immunotherapy, Active
1
2005
9
0.020
 Why?
Cerebral Hemorrhage
1
2006
108
0.020
 Why?
Aspartate Aminotransferases
1
2005
90
0.010
 Why?
Alanine Transaminase
1
2005
157
0.010
 Why?
Apolipoprotein B-100
1
2004
10
0.010
 Why?
Drug Utilization
1
2005
169
0.010
 Why?
Drug Administration Schedule
1
2007
786
0.010
 Why?
Arteriosclerosis
1
2004
88
0.010
 Why?
Chemical and Drug Induced Liver Injury
1
2005
137
0.010
 Why?
Angina Pectoris
1
2004
65
0.010
 Why?
Solubility
1
2004
245
0.010
 Why?
Enzyme-Linked Immunosorbent Assay
1
2006
852
0.010
 Why?
Troponin
1
2003
50
0.010
 Why?
Research Design
1
2009
1139
0.010
 Why?
Databases, Factual
1
2008
1357
0.010
 Why?
Heart Arrest
1
2004
339
0.010
 Why?
Pain
1
2005
756
0.010
 Why?
Retrospective Studies
2
2007
15657
0.010
 Why?
Brain
1
2007
2668
0.010
 Why?
Szarek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (305) concept(s)
_
Co-Authors Expand Description
See all (12) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)